User Preferences on Long-Acting Pre-Exposure Prophylaxis for HIV Prevention in Sub-Saharan Africa: A Scoping Review

Women

Adult women and adolescent girls and young women (AGYW) most commonly preferred LAIs over other long-acting products as they were perceived as having greater efficacy and favorable duration, and as suitably discreet. Women participating in the CAPRISA 082 study in South Africa who had previous experience using an implantable or injectable contraceptive method were more likely to choose that method for PrEP [14]. In a South African focus group, despite overall preference for LAIs over oral pills and the DVR, a few AGYW were dissuaded from injectable PrEP for fear of side effects similar to injectable contraceptives, such as menstruation cessation and weight gain [16].

Interest in the DVR was mixed. The ring was regarded positively among participants in the ASPIRE study, a multinational clinical trial of the DVR. Where women could select more than one product as “most preferred,” 94% of women selected the ring, compared with 39% for implants and 33% for LAIs [11]. However, many women expressed concern about discretion, such as whether their partner could feel the ring during intercourse or whether it could come out accidentally [7]. In most studies, DVR was less frequently preferred compared to LAIs [7,12,16,19]. Most AGYW in one focus group would not use the DVR due to perceived side effects, especially pain during intercourse, as well as concern for hygiene and use during menstruation [16].

Women reported broad interest in using implantable PrEP and stated that the benefits of an effective and long-lasting product outweighed potential drawbacks such as side effects or pain on insertion. They also expressed interest in a dual use product for PrEP and contraception in surveys and interviews. Since implants are already a common modality for extended-release contraceptives, a device which combines the two could be attractive to women seeking protection from both HIV and pregnancy. [7,15,17,20–24].

In a study of pregnant and postpartum women participating in the PrEP-PP and PrIMA-X trials in South Africa and Kenya, respectively, many voiced safety concerns for the mother and infant during pregnancy and breastfeeding. These women, most of whom had recent experience with oral PrEP, tended to prefer long-acting products over daily oral for their longer duration (especially in South Africa) and increased discretion (especially in Kenya) [12]. All pregnant AGYW interviewed in a study in South Africa would not use the DVR on account of perceived side effects [16]. Pregnant and postpartum women in multi-national focus groups mentioned fears of side effects ranging from exacerbation of pregnancy discomfort to severe outcomes such as miscarriage or birth defects. However, they were overall accepting of PrEP as long as it was safe and effective, and stressed the importance of choice and the ability to choose the formulation that worked best for them [25].

Female sex workers (FSWs)

Awareness of PrEP was low among FSWs in South Africa [20] and Tanzania [26], but after learning about PrEP most participants were willing to use it, particularly those who had recent symptoms or diagnosis of a sexually transmitted infection (STI). Many FSWs stated that protection by PrEP could enable them to have sex with clients without requiring condoms [20] or to accept condomless sex at a higher price [27], highlighting a potential concern regarding risk compensation. However, others viewed PrEP as a protective complement to condoms and stated that they would continue to use them to prevent STIs and pregnancy [26]. 86% of FSWs responded that they would likely use an implant in a South African DCE [21]. This high proportion of acceptability was complemented by qualitative interviews in South Africa [20], where FSWs commended the benefit of continuous protection and noted that it would be worth a brief amount of pain during insertion. Similarly, 88% of Tanzanian sex workers preferred LAIs over oral daily, although a smaller majority (58%) felt PrEP was generally worth taking. LAIs were considerably preferred over the DVR in interviews with South African FSWs; all sex workers stated they would not use the DVR on account of perceived side effects and concern that a client might notice the device [16].

Men

MSM tended to prefer LAIs over implants or oral pills. Among Nigerian MSM, preference for LAIs was associated with single relationship status, inconsistent condom use, and having a primary care provider [15]. Duration/dosing frequency was a highly prioritized product attribute for male participants. Oral PrEP-experienced young men in South Africa reported difficulty with daily dosing [7]. Men of all orientations valued privacy and discretion, though more men who have sex with women (MSW) valued being able to use PrEP without their partner knowing compared to MSM [28].

Preferences among heterosexual men were specifically assessed in two studies [5,18]. In a survey of urban heterosexual men in South Africa, 48% preferred LAIs compared to 33% who preferred oral and 20% who preferred condoms alone. Men who had children or who were less risk-averse were more likely to prefer LAIs. Men concerned with high risk of STIs other than HIV were more likely to prefer condoms over LAIs alone. As choices were discretely ranked, it was not clear how many men who preferred condoms for their protection against other STIs would prefer to use LAIs and condoms in combination. [18] In a mixed methods study conducted in South Africa, Uganda, and Zimbabwe among participants in the CHAPS trial, a majority of heterosexual male youth (65%) preferred on-demand oral PrEP compared to daily dosing. Those who did not believe they were exposed to HIV regularly enough to warrant taking a daily pill tended to prefer on-demand dosing in qualitative interviews. [5]

Duration

Product duration was the most important factor driving user preferences in many studies across demographics [7,10,12,23,28]. Oral PrEP-experienced pregnant and postpartum women most commonly cited product duration as a factor for switching to LAI [12]. Oral PrEP-experienced men also frequently reported difficulty adhering to a daily dosing schedule, especially on weekends, as well as difficulty swallowing the pill itself [7]. (Note that the most common oral PrEP formulation, emtricitabine-tenofovir, is a very large tablet [19 mm] which can be difficult to swallow even for users who take other, smaller tablet medications.) Male and female youth in a South African DCE valued product duration highly and were typically willing to trade their preferred product for one with a longer dosing frequency [23].

Notably, some youth in interviews in South Africa suggested an ideal formulation as a monthly rather than a daily pill [16]. This would reduce the burden of daily dosing for users who preferred an oral tablet over other long-acting formulations, such as pain associated with injections.

Efficacy

Many participants emphasized PrEP efficacy as an important determinant of product preference. They noted that efficacy was tied to longer duration due to the difficulty of adhering to a consistent dosing schedule, which hinders the observed effectiveness of oral PrEP. PrEP effectiveness was the strongest factor driving preference in several studies, notably among pregnant and postpartum women [12] and among youth populations [7,28]. High PrEP effectiveness outweighed participant concerns about side effects such as pain upon injection or product insertion.

Discretion

Discretion (i.e., being able to use a PrEP formulation without a partner or the community knowing) was a commonly mentioned concern, particularly among women and persons who did not wish to disclose their PrEP use to their partners. In several studies evaluating oral PrEP alongside LA formulations, including women [11], FSWs [26], and adults [24], participants expressed concern about stigma associated with daily pill use. They feared that others would think they had HIV if they discovered that they were taking a daily antiretroviral pill. Similarly, a visible preventive product could be seen as a mark of sexual indiscretion or promiscuity, as voiced in one South African focus group including participants of all genders and sexual orientations [29]. According to them, using PrEP could sow distrust or signal infidelity among users with romantic partners, and a woman who used PrEP might be seen as sexually promiscuous.

Notably, product discretion was described differently by different individuals. While many participants found daily pills indiscreet, others felt oral PrEP was the most discreet since it does not leave a mark like an injection [7]. Others, especially women, were concerned about their partner knowing about their PrEP use. Many participants expressed disinterest in the DVR for fear that their partner would feel the ring during intercourse, or that it might fall out and cause embarrassment. Concerns about a partner noticing signs of PrEP use were also mentioned relating to the implant; many participants in interviews disliked the notion of a visible device under the skin and preferred one that would not be seen by others.

Implant biodegradability

In general, participants preferred biodegradable implants which would not need to be removed by a provider, alleviating the need for an extra clinic visit and pain during removal [21,30]. South African healthcare providers also stressed this feature in qualitative interviews [31]. However, in one study in Kenya, many participants (especially FSWs) preferred a nonbiodegradable implant for its reversibility, as it could be removed if needed. Some also expressed fear about the effects of the degraded materials being absorbed into the body [24].

Logistical challenges

Long-acting formulations addressed the challenges of frequent visits to clinics or pharmacies, which participants variously described as overcrowded, lacking in privacy, and inconvenient or inaccessible [7,16]. These challenges drove preference for longer-duration products and for biodegradable implants, which require fewer visits.

Injection Fear

A common barrier to LAI acceptability was dislike or fear of needles. The current formulation of cabotegravir is injected in the buttock, but both males and females in South Africa tended to dislike this location for fear of discomfort especially while sitting [23,27]. Some young women were uncomfortable having to disrobe to receive an injection in the buttocks [27].

Side effects

Fear of real or perceived side effects was a salient factor influencing preference, especially for younger participants–about half of male and female youth in a study in Malawi reported being unwilling to use PrEP if they experienced side effects. Pain at injection site was the most frequently mentioned concern of LAIs, although youth in qualitative interviews stated that efficacy was a more significant factor even if the formulation was expected to be painful [7,28]. Similarly, pain upon insertion was a concern regarding implants, but participants generally felt that the benefits of an effective and long-lasting PrEP product outweighed the potential for pain. Qualitative interviews indicated a preference for a flexible versus a stiff implant for increased comfort.

Pain or discomfort also influenced acceptability of the DVR, especially discomfort during intercourse. Among pregnant and postpartum women in South Africa and Kenya, most of the participants who preferred oral PrEP over a vaginal ring did so on account of concern for physical discomfort [12]. In another study conducted among FSWs in Tanzania, participants expressed concerns about infertility associated with the DVR [26]. Conversely, in two studies conducted in Kenya and in South Africa, Uganda, and Zimbabwe, participants appreciated the reversibility of the DVR and implants, which could be removed if side effects arose [11,24].

Oral on-demand

Three studies conducted in South Africa, Uganda, and Zimbabwe assessed preference for oral on-demand PrEP compared to daily use, and one study in Eswatini, Kenya, and South Africa compared on-demand PrEP to a long-acting product. Overall, 60% of male youth [32] and 65% of youth MSM [5] preferred on-demand PrEP over daily oral tablets, with older youth tending to have greater preference for on-demand dosing. Having more frequent sexual intercourse was associated with a lower preference for on-demand PrEP and greater preference for daily oral PrEP. Participants who preferred on-demand PrEP cited not liking daily dosing, not considering oneself at frequent enough risk to warrant taking a daily pill, stigma, and pill burden.

Conversely, those who preferred daily use cited desire for continuous and/or improved protection and comparative ease of use by dosing every day instead of having to remember to take it before sex. One study examined the effect of post-traumatic stress disorder (PTSD) on preference in SSA youth and found no significant association between PTSD symptoms and a preference for on-demand versus daily PrEP, with a 61% vs 51% preference for on-demand dosing in those with and without PTSD symptoms, respectively [33]. South African men found oral on-demand, LAIs, and implants similarly acceptable, but if only one choice was available, they preferred a once-monthly pill (32%), six-month LAIs (28%) or implants (20%) over on-demand (2%) or a two-month injectable (5%) [34].